PRESS-RELEASE ·Filed Sep 11, 2026
Press release · Offering
Actionable Insight ▼ Bearish
The offering is small in absolute terms but significant relative to market cap. Monitor for stockholder approval date and registration statement filing — warrant exercises could add ~$5M cash.
Latest settled — T+20d
TPST ▼ -6.36% at T+20d
SHORT call ✓ call won +6.36% · α vs SPY +8.23% · entry $0.8117 → $0.7601
Latest observation: T+30 +19.97% FF3 residual α
T+1d
-3.38%
call +3.38% · α +2.93%
$0.7843
settled 6w ago
T+5d
+19.26%
call -19.26% · α -19.48%
$0.9680
settled 6w ago
T+20d
-6.36%
call +6.36% · α +8.23%
$0.7601
settled 18d ago
T+60d
Pending
in 6w
Price Chart
Loading chart...
Executive Summary
Tempest Therapeutics announced a private placement of ~3.1M shares and warrants at $0.805/unit, raising ~$2.5M in gross proceeds with potential additional ~$5M from warrant exercises.
Key Financial Metrics
Deal Value
$2.5M
Key Facts
- Private placement of 3,105,591 shares (or pre-funded warrants) plus series C and D warrants at $0.805/unit
- Gross proceeds ~$2.5M; potential additional ~$5M if warrants fully exercised
- Closing expected September 14, 2026; H.C. Wainwright acting as placement agent
- Proceeds for working capital and general corporate purposes
- Warrants exercisable after stockholder approval; series C expires 6 years, series D expires 3 years from later of approval/effectiveness date
- Market cap ~$13M; offering represents ~24% dilution on a pro forma basis (3.1M new shares vs ~13M outstanding)
Financial Impact
Gross proceeds ~$2.5M; potential warrant proceeds ~$5M; dilution ~24% of current outstanding shares
dilutioncashshare count
Risk Factors
- Dilution of ~24% from new shares and warrants
- Warrant exercise dependent on stockholder approval and registration effectiveness — no guarantee of additional proceeds
- Clinical-stage biotech with no approved products; cash runway extension needed
- Potential further dilution if additional capital raises required
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3360287 |
27 reports for TPST
77% Hit rate @ T+20 Went positive at some point 12 of 14 best @ T+60▲ +39.55%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEF 14A | $0.5102 | awaiting T+20 | — | $0.5100 (+0.04%) |
Oct 20, 2026 6d ago | DEFA14A | $0.5282 | awaiting T+20 | — | $0.5100 (−3.45%) |
Oct 20, 2026 6d ago | 8-K | $0.5282 | awaiting T+20 | — | $0.5100 (−3.45%) |
Oct 19, 2026 7d ago | 8-K | $0.5762 | awaiting T+20 | — | $0.5100 (−11.49%) |
Oct 2, 2026 25d ago | EFFECT | $0.8112 | awaiting T+20 | — | $0.5100 (+37.13%) |
Sep 25, 2026 4w ago | S-3 | $0.8316 $0.5102 | ▲ +38.65% | ▲ +38.62% | $0.5100 (+38.67%) |
Sep 17, 2026 5w ago | 8-K | $0.9680 $0.6240 | ▼ −35.54% | ▼ −35.74% | $0.5100 (−47.31%) |
Sep 16, 2026 5w ago | DEFA14A | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5100 (−43.02%) |
Sep 16, 2026 5w ago | 8-K | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5100 (−43.02%) |
Sep 11, 2026 6w ago | Press Release | $0.8117 $0.7601 | ▲ +6.36% | ▲ +8.23% | $0.5100 (+37.17%) |
Showing 10 of 27
US Market Status
Market Closed — Opens in 7h 32m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers